In-vitro maturation versus IVF: a cost-effectiveness analysis
| Autor: | S.C. Braam, Lan N. Vuong, Toan D Pham, Vu N A Ho, Ben W.J. Mol, Madelon van Wely |
|---|---|
| Přispěvatelé: | Graduate School, Amsterdam Reproduction & Development (AR&D), Center for Reproductive Medicine, APH - Methodology, APH - Personalized Medicine |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty In-vitro maturation Cost effectiveness Cost-Benefit Analysis Ovarian hyperstimulation syndrome Fertilization in Vitro 03 medical and health sciences 0302 clinical medicine Pregnancy medicine Humans Birth Rate Retrospective Studies 030219 obstetrics & reproductive medicine business.industry Obstetrics urogenital system Obstetrics and Gynecology Retrospective cohort study Odds ratio Cost-effectiveness analysis Antral follicle medicine.disease Confidence interval In Vitro Oocyte Maturation Techniques 030104 developmental biology Reproductive Medicine IVM IVF embryonic structures Cost-effectiveness Female business Live birth Developmental Biology |
| Zdroj: | Reproductive biomedicine online, 42(1), 143-149. Elsevier |
| ISSN: | 1472-6491 1472-6483 |
| Popis: | Research question How do costs and effects of in-vitro maturation (IVM) compare to IVF in women with a high antral follicle count (AFC)? Design This cost-effectiveness analysis (CEA) was based on data of a previous retrospective cohort study at IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam. Between July 2015 and December 2017, 608 women underwent IVM and 311 women IVF. The effectiveness measure for the CEA was cumulative live birth rate (LBR) after one completed cycle including subsequent cryo-cycles within 12 months of inclusion. Data were collected on resource use related to treatment, medication and pregnancy from the case report forms. The mean costs and effects, average cost differences and incremental cost-effectiveness ratios (ICER) were calculated using non-parametric bootstrap resampling to assess the effect of uncertainty in the estimates. Results Cumulative LBR after one completed cycle were 239/608 (39.3%) in the IVM group versus 155/311 (49.8%) in the IVF group (adjusted odds ratio 0.52, 95% confidence interval [CI] 0.30–0.89). Ovarian hyperstimulation syndrome (OHSS) did not occur in the IVM group versus 11/311 (3.5%) in the IVF group. The mean costs per couple were €4300 (95% CI €1371–18,798) for IVM and €6493 (95% CI €2204–20,136) for IVF. The ICER per additional live birth with IVF was €20,144 (95% CI €9116–50,418). Results were robust over a wide range of assumptions. Conclusions IVM is less expensive than IVF in women with a high AFC undergoing treatment with assisted reproductive technology, while leading to a slightly lower effectiveness in terms of cumulative LBR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect